Supplementary data

Figure S1: Analysis of purified WT and C300S Mpro by SDS-gel electrophoresis and RP-

HPLC/MALDI-TOF analysis. (A) Amino acid sequence for WT M^{pro}. The arrow indicates cysteine 300 which was mutated to serine300 in the mutant Mpro. Shown below the sequence is the calculated molecular weight (M_r) for WT and C300S Mpro. (B,F) LDS-gel electrophoresis of (B) purified WT M^{pro} and (F) purified C300S M^{pro}. In each gel, lanes 1 and 4 are molecular weight markers while lanes 2 and 5 are 4 µg and 8 µg of total protein loaded, respectively. (C,G) RP/HPLC showing the UV chromatogram at 205nm for (B) WT and (G) C300S M^{pro}. (D,H) The MALDI-TOF TIC chromatogram obtained by mass spectrometry for (D) WT and (H) C300S M^{pro}. (E,I) Protein deconvolution of the peaks in (D) and (H) showing the determined molecular weight obtained for (E) purified M^{pro} (33797.5 experimental vs 33796.5 calculated) and (I) C300S M^{pro} (33781.8 experimental vs 33780.4 calculated) after protein deconvolution. The insets in (E) and (I) show the molecular ion profile used for deconvolution of each M^{pro}. Separations were done on a Vydac C18 column using 95% buffer A (water 0.1% formic acid and 0.02% trifluoroacetic acid) and 5% buffer B (acetonitrile with 0.1% formic acid and 0.02% trifluoroacetic acid) with a 0.5 ml min⁻¹ flow rate and ramped to 65% buffer B with a 2% gradient for 30 minutes and then ramped to 100% for the next 5 min and then returned to starting conditions 2 min later. M^{pro} eluted at approximately 25 min. The TOF settings were as follows: gas temperature, 350°C; drying gas rate, 13 liters/min; nebulizer, 55 pounds per square inch gauge (psig); sheath gas temperature, 350°C; fragmenter, 350 V; skimmer, 65 V. Molecular weights were determined by protein deconvolution using Agilent Mass Hunter software (Agilent).

Figure S2: RP-HPLC/MALDI-TOF and UV chromatograms of chymotryptic digestions of native and monoglutathinylated M^{pro} preparations. Native and monoglutathionylated M^{pro} preparations were alkylated and digested with chymotrypsin as described in the materials and methods and then anlayzed by RP-HPLC/MALDI-TOF for the identification of M^{pro} peptides. (A) TIC chromatogram and (B) UV chromatogram (205 nm) of the native M^{pro} peptide digest. (C) TIC chromatogram and (D) UV chromatogram (205 nm) of the monoglutathionyated M^{pro} peptide digest. (E) TIC chromatogram and (F) UV chromatogram (205 nm) of the monoglutathionyated M^{pro} peptide digest following treatment with TCEP to reduce disulfide bonds.

Figure S3: Identification of glutathionylation at cysteines 156 and 300 in chymotryptic digests of monoglutathionylated M^{pro} preparations. The monoglutathionylated M^{pro} preparation was alkylated and digested with chymotrypsin as described in the materials and methods and then analyzed by RP-HPLC/MALDI-TOF for the identification of M^{pro} peptides. (A,B) The relevant area of the RP-HPLC/MS TIC chromatogram for the elution of chymotryptic peptides before (A) or after (B) treatment of the digested peptide preparation with TCEP to remove glutathione from glutathionylated peptides. (C,D) The corresponding RP-HPLC/MS UV chromatogram at 205 nm for the elution of chymotryptic peptides before (C) or after (D) treatment of the digested peptide preparation with TCEP to remove glutathione from glutathionylated peptides. The arrows in (A) and (C) indicate the location of eluting glutathionylated peptides 1^g,2^g and 3^g and in (B) and (D) indicate the location for the corresponding native peptides 1ⁿ,2ⁿ and 3ⁿ detected after reduction with TCEP. SSG denotes glutathionylated peptide. (E, G, I) Identification of peak 3^g (E), peak 2^g (G) and peak 1^g (I) by

ion extraction followed by monoisotopic deconvolution revealing masses corresponding to the glutathionylated chymotryptic peptides; 151:159, 295:305 and 295:306. Each chromatogram shows the extracted ion chromatogram using the predicted monoisotopic masses [M+H]⁺¹ for 151:159-SSG, 295:305-SSG and 295:306-SSG, respectively. (E,G,I) The insets in E, G, and I show the deconvoluted monoisotopic masses obtained for the peak with the monoisotopic masses indicated by dashed arrows. (F, H, and J) the same analysis as in E,G and I showing the absence of the glutathionylated peptides after TCEP reduction. (L,N, and P) Identification of peak 3^{n} (L), peak 2ⁿ (N) and peak 1ⁿ (P) by ion extraction followed by monoisotopic deconvolution revealing native peptides; 151:159, 295:305 and 295:306. Each chromatogram shows the extracted ion chromatogram using the predicted monoisotopic masses [M+H]⁺¹ for 151:159, 295:305 and 295:306, respectively. The insets in (L, N, and P) show the deconvoluted monoisotopic masses obtained for each peptide with the monoisotopic masses indicated by dashed arrows. For (K, M and O) the same analysis is done on the TCEP treated sample which reveals the loss of detection of the glutathionylated peptides. (L, N, and P) and identification of the native peptides (L) 151:159 (N) 295:305 and (P) 295:306 following TCEP treatment. Each panel shows the extracted ion chromatogram for the predicted monoisotopic masses 151:159, 295:305 and 295:306, respectively. The insets in (L, N, and P) show the deconvoluted monoisotopic masses obtained for each peptide with the monoisotopic masses indicated by dashed arrows. For (K, M and O) the same native molecular peptide ion extraction analysis is done on the bnon TCEP treated sample to show the absence of these peptides in the sample prior to TCEP treatment.

Figure S4: RP-HPLC/MALDI-TOF and UV chromatograms of trypsin/lysC digestions of native and monoglutathinylated M^{pro} preparations. Native and monoglutathionylated M^{pro}

preparations were alkylated and digested with trypsin/lysC as described in the materials and methods and then anlayzed by RP-HPLC/MALDI-TOF for the identification of M^{pro} peptides. (A) TIC chromatogram and (B) UV chromatogram (205 nm) of the native M^{pro} peptide digest. (C) TIC chromatogram and (D) UV chromatogram (205 nm) of the monoglutathionyated M^{pro} peptide digest. (E) TIC chromatogram and (F) UV chromatogram (205 nm) of the monoglutathionyated M^{pro} peptide digest following treatment with TCEP to reduce disulfide bonds.

Figure S5: Identification of Cys300 as a major target for glutathionylation based on trypsin/lysC digests of Monoglutathionylated Mpro preparations. The monoglutathionylated M^{pro} preparation was alkylated and digested with trypsin/lysC as described in the materials and methods and then analyzed by RP-HPLC/MALDI-TOF for the identification of M^{pro} peptides. (A,B) The relevant area of the RP-HPLC/MS TIC chromatogram for the elution of trypsin/lysC generated peptides before (A) or after (B) treatment of the digested peptide preparation with TCEP to remove glutathione from glutathionylated peptides. (C,D) RP-HPLC/MS UV chromatogram at 205 nm for the elution of trypsin/lysC generated peptides before (C) or after (D) treatment of the digested peptide preparation with TCEP to remove glutathione from glutathionylated peptides. The arrows in A and C indicate the location of eluting glutathionylated peptides 1,2 and 3 and in B and D indicate the location for the native peptides 1',2' and 3' detected after reduction with TCEP. SSG denotes glutathionylated peptide and (py) denotes the pyroglutamate form of the 299-306 peptide that results from spontaneous deamidation of peptides with N-terminal glutamyl residues {Wright, 1991 #28}. (E-I) Detection and identification of glutathionylated typ/lysC peptides 77:88-SSG, (G) 299:306-SSG py

(pyroglutamte form of the peptide) and (I) 295:306-SSG peptides. Each panel in E, G, and I shows the extracted ion chromatogram for the predicted monoisotopic masses for 77:88-SSG, 299:306-SSGpy, and 299:306-SSG, respectively. The insets in E, G, and I show the deconvoluted monoisotopic masses obtained for each glutathionylated peptide with the monoisotopic masses indicated by dashed arrows. (F-J) the same analysis is done on the TCEP treated sample which reveals the loss of detection of the glutathionylated peptides when carrying out the same mass extractions as E, G, and I. (L, N, and P) Detection and Identification of the native peptides (L) 77:88 (N) 299:306py and (P) 295:306 following TCEP treatment. Each panel shows the extracted ion chromatogram for the predicted monoisotopic masses for peptides 77:88, 299:306py and 299:306, respectively. The insets in L, N, and P show the deconvoluted monoisotopic masses obtained for each peptide with the monoisotopic masses indicated by dashed arrows. For K, M and O the same same analysis is done on the untreated sample which shows the absence of the peaks seen in L,N and P prior to TCEP treatment.

Figure S6: Glutathionylation of native and C300S M^{pro} after treatment with GSSG. Masses found by protein deconvolution from RPHPLC/MALDI -TOF analysis of samples in Figure 6A. (A) WT M^{pro} or (B) WT M^{pro} treated with 10 mM GSSG for 30 min. Masses found by protein deconvolution for (C) C300S M^{pro} or (D) C300S M^{pro} after treatment with 10 mM GSSG for 30 min. Samples were analyzed for protein glutathionylation following the assays performed in Figure 6A. (E) SEC/MALDI-TOF analysis of WT and (F) C300S M^{pro} after glutathionylating at pH 6.8 with 5 mM GSSG as described in material and methods. The upper number above each peak denotes the calculated mass, and the lower number denotes the abundance.

Supplemental Figure S7. Comparison of the local environment around Cys300 in dimeric SARS-CoV-1 Mpro and dimeric SARS-CoV-2 Mpro. (A) Ball and stick model for local environment around cys300 in SARS-CoV-1 Mpro showing the interactions with ASN214 and ASN299. Mpro (PDB ID 1UJ1 (SARS-CoV-1 Mpro apoenzyme at pH 6.0). (B) Ball and stick model for local environment around cys300 in SARS-CoV-2 Mpro showing the interactions with ASN214 and ASN299 carbonyls (PDB ID 7KT (SARS-CoV-2 Mpro apoenzyme at pH 6.5). Structural figures were produced with PyMOL v1.5.0.4 40.

Supplemental Figure S8. Amino acid alignment of the Main Protease from bat isolates (document ID's are MN996532.2 for RaTG13, MG772933.1 for ZC45, MG772934.1 for ZXC21 .nd MW681072.1 for SARS-CoV-2). Arrows indicate amino acids that are not fully conserved among all 4 sequences. There are two amino acid differences between SARS CoV-2 and RatG13 and 3 amino acid differences between SARS CoV-2 and both CoV-ZC45 and CoV-ZXC and those differences are highlighted in grey. Cysteine 300 is shown in the box.

Supplemental Figures for

Regulation of the Dimerization and Activity of SARS-CoV-2 Main Protease through Reversible Glutathionylation of Cysteine 300


by Davis et al.

А

amino acid sequence of WT Mpro

SGFRKMAFPSGKVEGCMVQVTCGTTTLNGLWLDDVVYCPRHVICTSEDMLNPNYEDLLIRKSNHNFLVQAGNVQLRVIGHSMQN CVLKLKVDTANPKTPKYKFVRIQPGQTFSVLACYNGSPSGVYQCAMRPNFTIKGSFLNGSCGSVGFNIDYDCVSFCYMHHMELP TGVHAGTDLEGNFYGPFVDROTAOAAGTDTTITVNVLAWLYAAVINGDRWFLNRFTTTLNDFNLVAMKYNYEPLTODHVDILGP LSAQTGIAVLDMCASLKELLQNGMNGRTILGSALLEDEFTPFDVVRQCSGVTFQ


WT M^{pro} Calculated molecular weight average ($M_{r (calc)}$): 33796.48 amu C300S M^{pro} Calculated molecular weight average (M_{r (calc)}): 33780.42 amu





32


30 32

1600









WT Mpro

preparation

35200 35400 35600

preparation

35600


C300S Mpro monoglutathionylated


34800

35000 35200 35400

34600

monoglutathionylated





Bat-SL-CoV-ZC45 Bat Mpro CoVZXC RaTG13 Mpro QHR SARS2 Mpro prot	1 1	SGFRKMAFPSGKVEGCMVQVTCGTTTLNGLWLDDVVYCPRHVICTSEDMLNPNYEDLLIR SGFRKMAFPSGKVEGCMVQVTCGTTTLNGLWLDDVVYCPRHVICTSEDMLNPNYEDLLIR SGFRKMAFPSGKVEGCMVQVTCGTTTLNGLWLDDVVYCPRHVICTSEDMLNPNYEDLLIR SGFRKMAFPSGKVEGCMVQVTCGTTTLNGLWLDDVVYCPRHVICTSEDMLNPNYEDLLIR	60 60 60 60
Bat-SL-CoV-ZC45 Bat Mpro CoVZXC RaTG13 Mpro QHR SARS2 Mpro prot	61 61	KSNHNFLVQAGNVQLRVVGHSMQNCVLKLKVDTANPKTPKYKFVRIQPGQTFSVLACYNG KSNHNFLVQAGNVQLRVVGHSMQNCVLKLKVDTANPKTPKYKFVRIQPGQTFSVLACYNG KSNHNFLVQAGNVQLRVIGHSMQNCVLKLKVDTANTKTPKYKFVRIQPGQTFSVLACYNG KSNHNFLVQAGNVQLRVIGHSMQNCVLKLKVDTANPKTPKYKFVRIQPGQTFSVLACYNG	120 120
Bat Mpro CoVZXC RaTG13 Mpro QHR	121 121	SPSGVYQCAMRPNFTIKGSFLNGSCGSVGFNIDYDCVSFCYMHHMELPTGVHAGTDLEGT SPSGVYQCAMRPNFTIKGSFLNGSCGSVGFNIDYDCVSFCYMHHMELPTGVHAGTDLEGT SPSGVYQCAMRPNFTIKGSFLNGSCGSVGFNIDYDCVSFCYMHHMELPTGVHAGTDLEGT SPSGVYQCAMRPNFTIKGSFLNGSCGSVGFNIDYDCVSFCYMHHMELPTGVHAGTDLEGN	180 180
Bat Mpro CoVZXC RaTG13 Mpro QHR	181 181	T FYGPFVDRQTAQAAGTDTTITVNVLAWLYAAVINGDRWFLNRFTTTLNDFNLVAMKYNYE FYGPFVDRQTAQAAGTDTTITVNVLAWLYAAVINGDRWFLNRFTTTLNDFNLVAMKYNYE FYGPFVDRQTAQAAGTDTTITVNVLAWLYAAVINGDRWFLNRFTTTLNDFNLVAMKYNYE ***********************************	240 240
Bat Mpro CoVZXC RaTG13 Mpro QHR	241 241	PLTQDHLDILGPLSAQTGIAVLDMCASLKELLQNGMNGRTILGSALLEDEFTPFDVVRCC PLTQDHLDILGPLSAQTGIAVLDMCASLKELLQNGMNGRTILGSALLEDEFTPFDVVRCC PLTQDHVDILGPLSAQTGIAVLDMCASLKELLQNGMNGRTILGSALLEDEFTPFDVVRCC ******	300
Bat-SL-CoV-ZC45 Bat Mpro CoVZXC RaTG13 Mpro QHR SARS2 Mpro prot	301 301	SGVTFQ 306 SGVTFQ 306	

Peptide Number	Peptide	$M_{r (calc)}$	M _{r (expt)}	Delta	R.T.
	From:To				
1	9:31 (cys16 & 22)	2630.22	ND	-	-
2	38:54 (cys38 & 44)	2240.96	2239.41.	1.55	24
3	67:101 (cys85)	3987.16	ND	-	-
41	113:118 (cys117)	779.35	779.33	-0.02	17.7
5a ¹	127:134 (cys128)	1090.47	1090.45	-0.02	16.9/17.3
5b ¹	py127:134 (cys128)	1073.47	1073.44	-0.03	18.9/19.3
61	141:150 (cys145)	1064.46	1064.44	-0.02	18.1
7a ¹	155:159 (cys156)	694.26	694.36	0.1	9.7
7b ¹	151:159 (cys156)*	1199.43	1199.46	0.03	22.5
8	160:161 (cys161)	409.13	ND	-	-
9	240:291 (cys265)	5560.84	ND	-	-
10a ¹	295:305 (cys300)	1334.63	1334.61	-0.02	19
10b ¹	295:306 (cys300)**	1462.69	1462.66	-0.03	17.4
111	141:150 (cys-sg 145)	1244.48	1240.67	-3.81	13.7
11n ¹	141:150 (native)	939.4	939.4	0	15.1
121	151:159 (cys-sg 156) *	1379.3	1379.47	0.17	19
12n ¹	151:159 (native)	1074.42	1074.41	-0.01	20.7
131	295:306 (cys-sg 300)	1642.7	1642.68	-0.02	13.7
13n ¹	295:306 (native) **	1337.63	1337.61	-0.02	15.5
141	295:305 (cys-sg 300)	1514.66	1514.62	-0.04	14.9
14n ¹	295:305 (native)	1209.58	1209.56	-0.02	16.9
15	4:8	651.34	651.35	0.01	9.7***
16	32:37	722.34	722.34	-0.02	13.3
17	55:66	1484.76	1482.75	-2.01	19.8
18	104:112	1044.56	1044.56	0	14.4
19	119:126	779.33	779.34	0.01	17.7
20	135:140	651.35	651.35	0	9.7***
21	151:154	523.22	523.23	0.01	4.1
22	162:181	2191.97	2192.95	0.02	20.8
23	186:207	2330.18	2328.94	-2.18	26
24	210:218	1000.5	1000.49	-0.01	14.7
25	220:223	548.29	548.3	0.01	8.2
26	224:230	810.37	810.36	-0.01	14.1
27	231:237	837.43	ND	-	-

Table S1: Peptides calculated and observed after cysteine alkylation and chymotrypsin digestion of M^{pro} or monoglutathionylated M^{pro} preparations

Peptides 1-10 are the cysteine containing peptides predicted and, where indicated, identified after chymotrypsin digestion. Peptides 11-14 are the glutathionylated and native forms of peptides identified. Peptides 16-27 are the non-cysteine containing peptides predicted and, where indicated, identified after chymotrypsin digestion. The -sg indicates glutathionylated peptide. *These peptides containing cysteine 156 occur due to lack of cleavage at the 154:155 predicted chymotryptic cleavage site. ** These peptides containing Cys300 occur due to incomplete cleavage at the 305:306 predicted chymotryptic cleavage site. ND=Not Detected

Peptide Number	Peptide	$M_{r (calc)}$	M _{r (expt)}	Delta	R.T.
	From:To				
1	13:40 (cys16,22,38)	3446.56	3448.51	1.95	28.2
2a	41:60 (cys44)	2499.17	2500.14	0.97	24.6
2b	41:61 (cys44) *	2627.26	2628.23	0.97	23.8
3	77:88 (cys85)	1452.71	1452.7	-0.01	17.3
4a	106:131 (cys117,128)	3026.37	ND	ND	ND
4b	106:137 (cys117,128) **	3726.76	3728.7	1.94	26
5	138:188 (cys145,156, 161)	5561.38	ND	ND	ND
6	237:269 (cys265)	3699.81	3701.75	1.94	29.2
7a	299:306 (cys300)	993.41	993.41	0	15.1
7b	299:306 (cys300)(pGlu) ***	976.41	976.38	-0.03	17.2
8	77:88 (cys-sg 85)	1632.74	1632.71	-0.03	13.5
8n	77:88 (native cys 85)	1327.66	1327.64	-0.02	14.7
9	299:306 (cys-sg 300)	1173.44	1173.42	-0.02	10.9
9n	299:306 (native cys 300)	868.36	868.36	0	11.2
10	299:306 (pGlu) (cys-sg 300)	1156.44	1156.4	-0.04	12.7
10n	299:306 (pGlu) (nat cys300)***	851.36	851.33	-0.03	14
11	1:4	465.22	465.23	0.01	2.9
12	6:12	736.34	736.35	-0.01	10.8
13	62:76	1695.87	1695.86	-0.01	18.7
14	91:97	734.37	ND	ND	ND
15	132:137	718.39	718.37	-0.02	8.8
16	189:217	3032.55	3032.54	-0.01	25.6
17	218:222	734.38	ND	ND	ND
18	223:236	1613.8	1613.78	-0.02	23.7
19	270:279	1130.54	1130.53	0.01	11.9

Table S2: RP/HPLC/MALDI-TOF MS Identification of peptides from trypsin/lysC digestion of M^{pro} or monoglutathionylated M^{pro} preparation

20 280:298

Peptides 1-7 are the cysteine containing peptides predicted and, where indicated, identified after trypsin/lysC digestion. Peptides 8-10 are the glutathionylated and native forms of peptides identified. Peptides 11-20 are the non-cysteine containing peptides predicted and, where indicated, identified after trypsin/lysC digestion. The -sg indicates glutathonylated peptide. *This peptide (41:61) was the result of incomplete cleavage at the 60/61 cleavage site. **This peptide was the result of incomplete digestion at the 131/132 cleavage site. ***These peptides are the result of the spontaneous deamidation that occurs with peptides containing an N-terminal glutamine, the retention times and molecular masses for this peptide were confirmed with the use of synthetic peptides were confirmed with the use of synthetic peptides were confirmed with the use of synthetic patients were run on RP-HPLC/MS. The retention times (RT) and molecular masses for the Cys300 peptides were confirmed with the use of synthetic patients were run on RP-HPLC/MALDI-TOF as native, alkylated or glutathionylated peptides. Peptide samples were analyzed without (-) and with (+) TCEP to remove glutathione moieties. Shown are the calculated native masses [$M_{r(calc)}$] and the experimental masses [$M_{r(expt0)}$]. The full TIC and 205 nm UV chromatograms for these analyses can be found in supplemental material (see Figure S5C-S5F in supplemental material). ND=Not Detected